Immune-based strategies are the most promising treatments to improve cancer disease control. Early clinical trials are ongoing to test the safety and feasibility of immune-based therapies for gastrointestinal cancers. However, to date, immunotherapy has been only an experimental option for these diseases and a better understanding of their molecular, cellular, structural and clinical dissimilarities is crucial in the generation of tailored immunotherapeutic treatments. In this review, we will summarize the key mechanisms that regulate the action of immune system in cancer and the different immune-based approaches aimed at improving disease control in patients with advanced disease. We will then move on to discussing the current immunotherapeutic approaches in two types of gastrointestinal (colo-rectal and pancreatic) cancers, whose immune microenvironment has been lately object of intense analyses and has emerged as an important determinant of clinical outcome.

Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness / G. Di Caro, G.F. Castino, F. Bergomas, N. Cortese, M. Chiriva-Internati, F. Grizzi, F. Marchesi. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - 14:10(2014), pp. 1219-1228. [10.1586/14737140.2014.947277]

Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness

F. Marchesi
Ultimo
2014

Abstract

Immune-based strategies are the most promising treatments to improve cancer disease control. Early clinical trials are ongoing to test the safety and feasibility of immune-based therapies for gastrointestinal cancers. However, to date, immunotherapy has been only an experimental option for these diseases and a better understanding of their molecular, cellular, structural and clinical dissimilarities is crucial in the generation of tailored immunotherapeutic treatments. In this review, we will summarize the key mechanisms that regulate the action of immune system in cancer and the different immune-based approaches aimed at improving disease control in patients with advanced disease. We will then move on to discussing the current immunotherapeutic approaches in two types of gastrointestinal (colo-rectal and pancreatic) cancers, whose immune microenvironment has been lately object of intense analyses and has emerged as an important determinant of clinical outcome.
biomarkers; colo-rectal cancer; immunotherapy; pancreatic adenocarcinoma; tumor microenvironment; Pharmacology (medical); Oncology
Settore MED/04 - Patologia Generale
2014
Article (author)
File in questo prodotto:
File Dimensione Formato  
Marchesi Expert Rev .pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 298.47 kB
Formato Adobe PDF
298.47 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/252022
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
  • OpenAlex ND
social impact